- Home
- JFR vs PCRX Comparison
JFR vs PCRX Comparison
Compare JFR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFR
- PCRX
- Stock Information
- Founded
- JFR 2004
- PCRX 2006
- Country
- JFR United States
- PCRX United States
- Employees
- JFR N/A
- PCRX N/A
- Industry
- JFR Trusts Except Educational Religious and Charitable
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- JFR Finance
- PCRX Health Care
- Exchange
- JFR Nasdaq
- PCRX Nasdaq
- Market Cap
- JFR 1.1B
- PCRX 1.2B
- IPO Year
- JFR N/A
- PCRX 2011
- Fundamental
- Price
- JFR $8.19
- PCRX $25.12
- Analyst Decision
- JFR
- PCRX Buy
- Analyst Count
- JFR 0
- PCRX 9
- Target Price
- JFR N/A
- PCRX $29.89
- AVG Volume (30 Days)
- JFR 621.7K
- PCRX 745.0K
- Earning Date
- JFR 01-01-0001
- PCRX 05-08-2025
- Dividend Yield
- JFR 11.31%
- PCRX N/A
- EPS Growth
- JFR N/A
- PCRX N/A
- EPS
- JFR N/A
- PCRX N/A
- Revenue
- JFR N/A
- PCRX $702,772,000.00
- Revenue This Year
- JFR N/A
- PCRX $9.48
- Revenue Next Year
- JFR N/A
- PCRX $11.31
- P/E Ratio
- JFR N/A
- PCRX N/A
- Revenue Growth
- JFR N/A
- PCRX 3.08
- 52 Week Low
- JFR $7.61
- PCRX $11.16
- 52 Week High
- JFR $8.82
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- JFR 52.79
- PCRX 48.10
- Support Level
- JFR $8.17
- PCRX $25.08
- Resistance Level
- JFR $8.27
- PCRX $27.34
- Average True Range (ATR)
- JFR 0.07
- PCRX 1.16
- MACD
- JFR 0.03
- PCRX -0.18
- Stochastic Oscillator
- JFR 80.49
- PCRX 48.85
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.